Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05563831
What this trial is testing

National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

Who this might be right for
PIK3CA-related Overgrowth SpectrumCLOVES SyndromeKlippel Trenaunay Syndrome+6 more
Institut National de la Santé Et de la Recherche Médicale, France 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT05230810
What this trial is testing

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Who this might be right for
HER2-positive Metastatic Breast Cancer
Criterium, Inc. 40
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Large-scale testing (Phase 3)Active Not RecruitingNCT04191499
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 325
Testing effectiveness (Phase 2)Active Not RecruitingNCT05810870
What this trial is testing

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
MedSIR 14
Testing effectiveness (Phase 2)Study completedNCT02728258
What this trial is testing

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more
NRG Oncology 11
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Testing effectiveness (Phase 2)Study completedNCT01704703
What this trial is testing

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

Who this might be right for
Stage IV Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 72
Testing effectiveness (Phase 2)Study completedNCT02506556
What this trial is testing

Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Peter MacCallum Cancer Centre, Australia 38
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Testing effectiveness (Phase 2)Study completedNCT03056755
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 383
Early research (Phase 1)Active Not RecruitingNCT04192981
What this trial is testing

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Who this might be right for
Brain MetastasesLeptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center 21
Testing effectiveness (Phase 2)Looking for participantsNCT05455619
What this trial is testing

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast CancerMetastatic Breast Cancer
SynDevRx, Inc. 52
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Not applicableUnknownNCT05750693
What this trial is testing

PIK3CA in HER2+ BC and pCR Trial

Who this might be right for
HER2-positive Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 58
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07486648
What this trial is testing

Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

Who this might be right for
Lung Cancer (NSCLC)Lung Cancer (Non-Small Cell)Advanced Non-small-cell Lung Cancer
Shanxi Province Cancer Hospital 53
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Testing effectiveness (Phase 2)Study completedNCT01625286
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

Who this might be right for
Advanced or Metastatic Breast CancerER+ve Advanced or Metastatic Breast Cancer
AstraZeneca 148
Testing effectiveness (Phase 2)Study completedNCT01816594
What this trial is testing

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

Who this might be right for
HER2-positive Newly Diagnosed, Primary Breast Cancer
Novartis Pharmaceuticals 50
Next Page